Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanisms of drug resistance

Protein Science

Volumn 9, Issue 10, 2000, Pages 1898-1904

  Hong, Lin ^a   Zhang, Xuenjun C ^a   Hartsuck, Jean A ^a   Tang, Jordan ^a,b,c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

AIDS; Drug resistance; HIV protease; Mutation; Saquinavir

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; MUTANT PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; VIRUS ENZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CATALYSIS; CRYSTAL STRUCTURE; ENZYME KINETICS; ENZYME STRUCTURE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; X RAY CRYSTALLOGRAPHY;

EID: 0033778181     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.9.10.1898     Document Type: Article

References (27)

1. Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors
2. The CCP4 suite: Programs for protein crystallography Number 4 Collaborative Computational Project
3. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
4. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials
5. Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of gag precursor
6. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959
7. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo
8. An 11-kDa form of human immunodeficiency virus protease expressed in Escherichia coli is sufficient for enzymatic activity
9. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases
10. Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity
11. Kinetic studies of human immunodeficiency virus type I protease and its active-site hydrogen bond mutant A28S
12. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
13. Characterization of human immunodeficiency virus type I mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959
14. Improved methods for building protein models in electron density maps and the location of errors in these models
15. Active human immunodeficiency virus protease is required for viral infectivity
16. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere
17. X-ray analysis of HIV-1 proteinase at 2.7 A resolution confirms structural homology among retroviral enzymes
18. SURFNET: A program for visualizing molecular surfaces, cavities, and intermolecular interactions
19. A program to check the stereo chemical quality of protein structures
20. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: Relationship to drug resistance
21. Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex
22. AMoRe: An automated package for molecular replacement
23. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor
24. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A
25. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease
26. Identification of a loop outside the active site cavity of the human immunodeficiency virus proteases which confers inhibitor specificity
27. Structure-based inhibitors of HIV-1 protease